Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The PROGRESS Trial, officially titled ‘The PROGRESS Trial: A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement,’ aims to evaluate the safety and effectiveness of the Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in patients with moderate, calcific aortic stenosis. This study is significant as it explores treatment options for aortic stenosis, a common heart valve disease.
The study tests the intervention of Transcatheter Aortic Valve Replacement (TAVR) using the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA devices, aiming to provide a less invasive treatment alternative for patients.
This is an interventional study with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment. Participants are assigned to either the TAVR group or a Clinical Surveillance group.
The study began on October 12, 2021, and is currently recruiting. The last update was submitted on July 8, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact Edwards Lifesciences Corp.’s stock performance and investor sentiment, as successful results may enhance the company’s market position in the cardiovascular device industry. Competitors in the heart valve market will be closely monitoring these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.